IL150484A0 - Novel colloid synthetic vectors for gene therapy - Google Patents

Novel colloid synthetic vectors for gene therapy

Info

Publication number
IL150484A0
IL150484A0 IL15048400A IL15048400A IL150484A0 IL 150484 A0 IL150484 A0 IL 150484A0 IL 15048400 A IL15048400 A IL 15048400A IL 15048400 A IL15048400 A IL 15048400A IL 150484 A0 IL150484 A0 IL 150484A0
Authority
IL
Israel
Prior art keywords
gene therapy
synthetic vectors
novel colloid
colloid synthetic
novel
Prior art date
Application number
IL15048400A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL150484A0 publication Critical patent/IL150484A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/14—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic the nitrogen atom of the amino group being further bound to hydrocarbon groups substituted by amino groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL15048400A 1999-12-30 2000-12-28 Novel colloid synthetic vectors for gene therapy IL150484A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47530599A 1999-12-30 1999-12-30
PCT/EP2000/013300 WO2001049324A2 (en) 1999-12-30 2000-12-28 Novel colloid synthetic vectors for gene therapy

Publications (1)

Publication Number Publication Date
IL150484A0 true IL150484A0 (en) 2002-12-01

Family

ID=23887011

Family Applications (3)

Application Number Title Priority Date Filing Date
IL15048400A IL150484A0 (en) 1999-12-30 2000-12-28 Novel colloid synthetic vectors for gene therapy
IL150484A IL150484A (en) 1999-12-30 2002-06-27 Colloid synthetic vectors for gene therapy
IL207404A IL207404A0 (en) 1999-12-30 2010-08-04 Novel colloid synthetic vectors for gene therapy

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL150484A IL150484A (en) 1999-12-30 2002-06-27 Colloid synthetic vectors for gene therapy
IL207404A IL207404A0 (en) 1999-12-30 2010-08-04 Novel colloid synthetic vectors for gene therapy

Country Status (8)

Country Link
US (1) US20030166601A1 (xx)
EP (1) EP1242609A2 (xx)
JP (1) JP2003519199A (xx)
CN (2) CN101041079A (xx)
AU (1) AU3366901A (xx)
CA (1) CA2395636A1 (xx)
IL (3) IL150484A0 (xx)
WO (1) WO2001049324A2 (xx)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ259399A0 (en) * 1999-09-01 1999-09-23 Lustre Investments Pte Ltd Therapeutic agents
AU2002348163A1 (en) * 2001-11-02 2003-05-19 Intradigm Corporation Therapeutic methods for nucleic acid delivery vehicles
US6600075B1 (en) * 2001-11-13 2003-07-29 E. I. Du Pont De Nemours And Company Process for the preparation of tertiaŕy amines from primary amines and nitriles
CA2481979A1 (en) * 2002-04-11 2003-10-16 Yasushi Taguchi Peptides chemically modified with polyethylene glycol
US9050378B2 (en) 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
US8057821B2 (en) * 2004-11-03 2011-11-15 Egen, Inc. Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof
US7964571B2 (en) 2004-12-09 2011-06-21 Egen, Inc. Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
US9505867B2 (en) * 2005-05-31 2016-11-29 Ecole Polytechmique Fédérale De Lausanne Triblock copolymers for cytoplasmic delivery of gene-based drugs
EP2476756A1 (en) 2005-06-15 2012-07-18 Massachusetts Institute of Technology Amine-containing lipids and uses thereof
JP5059312B2 (ja) * 2005-09-16 2012-10-24 Ｈｏｙａ株式会社 高分散性リン酸カルシウム系化合物ナノ粒子及びその製造方法
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
EP2183297A2 (en) * 2007-07-31 2010-05-12 PolyPlus Transfection Method for manufacturing linear polyethylenimine (pei) for transfection purpose and linear pei obtained with such method
US9144546B2 (en) 2007-08-06 2015-09-29 Clsn Laboratories, Inc. Nucleic acid-lipopolymer compositions
US20090042825A1 (en) * 2007-08-06 2009-02-12 Majed Matar Composition, method of preparation & application of concentrated formulations of condensed nucleic acids with a cationic lipopolymer
JP2010538678A (ja) * 2007-09-18 2010-12-16 イントラドイグム コーポレーション Ｋ−ｒａｓｓｉＲＮＡ含有組成物及びそれらの使用法
US20100280097A1 (en) * 2007-09-18 2010-11-04 Intradigm Corporation Compositions comprising hif-1 alpha sirna and methods of use thereof
US9095568B2 (en) * 2007-09-26 2015-08-04 Mark Berninger Therapeutic and vaccine polyelectrolyte nanoparticle compositions
CN101970687A (zh) * 2007-11-09 2011-02-09 东北大学 用于体内基因输送的自组装胶束样纳米颗粒
CA2717496A1 (en) * 2008-03-12 2009-09-17 Intradigm Corporation Compositions comprising notch1 sirna and methods of use thereof
MX353900B (es) * 2008-11-07 2018-02-01 Massachusetts Inst Technology Lipidoides de aminoalcohol y usos de los mismos.
JP5906184B2 (ja) 2009-06-22 2016-04-20 バーナム インスティテュート フォー メディカル リサーチ Ｃ末端エレメントを有するペプチドおよびタンパク質を使用する方法および組成物
RS58405B1 (sr) 2009-12-01 2019-04-30 Translate Bio Inc Stereoidni derivati za isporuku irnk u humanim genetskim oboljenjima
US20130011333A1 (en) * 2010-01-18 2013-01-10 Board Of Regents, The University Of Texas System Methods and Compositions for Nanoparticle-Mediated Cancer Cell-Targeted Delivery
CA2793663C (en) 2010-03-19 2019-03-19 The Administrators Of The Tulane Educational Fund Polyplex gene delivery vectors
EP2609135A4 (en) 2010-08-26 2015-05-20 Massachusetts Inst Technology POLY (BETA-AMINO ALCOHOLS), THEIR PREPARATION AND USES THEREOF
AU2011352204B2 (en) * 2010-12-29 2015-05-21 Arrowhead Pharmaceuticals, Inc. In vivo polynucleotide delivery conjugates having enzyme sensitive linkages
WO2012118778A1 (en) 2011-02-28 2012-09-07 Sanford-Burnham Medical Research Institute Truncated car peptides and methods and compositions using truncated car peptides
WO2012135025A2 (en) 2011-03-28 2012-10-04 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
EP2715291A4 (en) 2011-05-31 2015-10-21 Airware Inc NON-DISPERSIVE GAS SENSORS WITH ABSORPTION INFRARED ABSORPTION (NDIR)
RS59037B1 (sr) 2011-06-08 2019-08-30 Translate Bio Inc Kompozicije lipidnih nanočestica i postupci za isporuku irnk
US10179801B2 (en) 2011-08-26 2019-01-15 Sanford-Burnham Medical Research Institute Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides
US20130072854A1 (en) * 2011-09-19 2013-03-21 General Electric Company Microbubble complexes and methods of use
PE20150041A1 (es) 2011-10-27 2015-01-28 Massachusetts Inst Technology Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco
WO2013075244A1 (en) * 2011-11-24 2013-05-30 Pu Chen Peptide sequence design and use thereof for peptide-mediated sirna delivery
CN102657843A (zh) * 2012-06-05 2012-09-12 云南民族大学 抗菌肽组合物及其制备方法
EP2859102A4 (en) 2012-06-08 2016-05-11 Shire Human Genetic Therapies NUCLEASE RESISTANT POLYNUCLEOTIDES AND USES THEREOF
JP2015524410A (ja) 2012-07-18 2015-08-24 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． エポキシケトン系プロテアソーム阻害剤のリポソーム組成物
WO2014028487A1 (en) 2012-08-13 2014-02-20 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
WO2014153114A1 (en) * 2013-03-14 2014-09-25 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
AU2014236396A1 (en) 2013-03-14 2015-08-13 Shire Human Genetic Therapies, Inc. Methods for purification of messenger RNA
EP3446712A1 (en) 2013-03-14 2019-02-27 Translate Bio Ma, Inc. Cftr mrna compositions and related methods and uses
WO2014179562A1 (en) 2013-05-01 2014-11-06 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
EP3044314B1 (en) 2013-07-12 2019-04-10 SeNa Research, Inc. Methods and compositions for interference with dna polymerase and dna synthesis
US10711106B2 (en) 2013-07-25 2020-07-14 The University Of Chicago High aspect ratio nanofibril materials
US20160228567A1 (en) * 2013-10-21 2016-08-11 Northeastern University Hypoxia-Targeted Delivery System for Pharmaceutical Agents
US11224642B2 (en) 2013-10-22 2022-01-18 Translate Bio, Inc. MRNA therapy for argininosuccinate synthetase deficiency
MX2016005238A (es) 2013-10-22 2016-08-12 Shire Human Genetic Therapies Formulaciones de lipidos para la administracion de acido ribonucleico mensajero.
EA034103B1 (ru) 2013-10-22 2019-12-27 Транслейт Био, Инк. СПОСОБ ЛЕЧЕНИЯ ФЕНИЛКЕТОНУРИИ С ПРИМЕНЕНИЕМ мРНК
BR112016024632A2 (pt) 2014-04-25 2018-01-30 Shire Human Genetic Therapies métodos de purificação de rna mensageiro
EP3148552B1 (en) 2014-05-30 2019-07-31 Translate Bio, Inc. Biodegradable lipids for delivery of nucleic acids
AU2015279968B2 (en) 2014-06-24 2019-11-14 Translate Bio, Inc. Stereochemically enriched compositions for delivery of nucleic acids
WO2016004202A1 (en) 2014-07-02 2016-01-07 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
JP6800410B2 (ja) 2015-06-19 2020-12-16 マサチューセッツ インスティテュート オブ テクノロジー アルケニル置換２，５−ピペラジンジオン、および、対象または細胞に剤を送達するための組成物におけるそれらの使用
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
JP2020500020A (ja) 2016-11-14 2020-01-09 ノバルティス アーゲー 融合誘導性タンパク質ｍｉｎｉｏｎに関連する組成物、方法、および治療上の使用
EP3565535A4 (en) 2017-01-05 2020-12-30 Fred Hutchinson Cancer Research Center SYSTEMS AND METHODS FOR IMPROVING THE EFFECTIVENESS OF A VACCINE
MX2019010155A (es) 2017-02-27 2020-12-10 Translate Bio Inc Arnm de cftr optimizado por codón novedoso.
WO2018204392A1 (en) 2017-05-02 2018-11-08 Stanford Burnham Prebys Medical Discovery Institute Tumor associated monocyte/macrophage binding peptide and methods of use thereof
MA49138A (fr) 2017-05-16 2020-03-25 Translate Bio Inc Traitement de la fibrose kystique par administration d'arnm à codons optimisés codant pour la cftr
CA3081758A1 (en) * 2017-11-06 2019-05-09 Nitto Denko Corporation Fusogenic compounds for delivery of biologically active molecules
CN109055432B (zh) * 2018-08-16 2020-10-13 南京科佰生物科技有限公司 慢病毒感染试剂及其制备方法与应用
AU2019325702A1 (en) 2018-08-24 2021-02-25 Translate Bio, Inc. Methods for purification of messenger RNA
US20220119450A1 (en) 2019-02-04 2022-04-21 University Of Tartu Bi-specific extracellular matrix binding peptides and methods of use thereof
CN111821421B (zh) * 2020-08-13 2021-11-02 上海交通大学 一种肠道缓释牛初乳海参肽咀嚼片及其制备方法
CN115947671B (zh) * 2022-11-21 2023-09-26 荣灿生物医药技术(上海)有限公司 一种含氨基甲酸酯键的脂质化合物及其应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4482743A (en) * 1983-07-28 1984-11-13 Texaco Inc. Hydroxyalkyl bis(dialkylaminoalkyl)amine manufacture
US5714166A (en) * 1986-08-18 1998-02-03 The Dow Chemical Company Bioactive and/or targeted dendrimer conjugates
US5776894A (en) * 1988-12-05 1998-07-07 Novartis Ag Chelated somatostatin peptides and complexes thereof, pharmaceutical compositions containing them and their use in treating tumors
US5705187A (en) * 1989-12-22 1998-01-06 Imarx Pharmaceutical Corp. Compositions of lipids and stabilizing materials
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US6113946A (en) * 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5871710A (en) * 1992-09-04 1999-02-16 The General Hospital Corporation Graft co-polymer adducts of platinum (II) compounds
US5574142A (en) * 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
US5395619A (en) * 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5541230A (en) * 1993-11-05 1996-07-30 Us Health Therapeutic polyamines
US5670347A (en) * 1994-05-11 1997-09-23 Amba Biosciences Llc Peptide-mediated gene transfer
US5777153A (en) * 1994-07-08 1998-07-07 Gilead Sciences, Inc. Cationic lipids
FR2722506B1 (fr) * 1994-07-13 1996-08-14 Rhone Poulenc Rorer Sa Composition contenant des acides nucleiques, preparation et utilisations
US5837533A (en) * 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5783178A (en) * 1994-11-18 1998-07-21 Supratek Pharma. Inc. Polymer linked biological agents
US5656611A (en) * 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5830430A (en) * 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
CA2223088A1 (en) * 1995-06-07 1996-12-19 Bob Dale Brown Novel carbamate-based cationic lipids
CA2223179A1 (en) * 1995-06-07 1996-12-19 Bob Dale Brown Phosphonic acid-based cationic lipids
US6020526A (en) * 1995-07-21 2000-02-01 Genta, Incorporated Amide-based cationic lipids
US5919442A (en) * 1995-08-11 1999-07-06 Dendritech, Inc. Hyper comb-branched polymer conjugates
CA2202928A1 (en) * 1995-08-17 1997-02-27 Wilhelmus Everhardus Hennink Poly(organo)phosphazenes for use in synthetic transfection systems
AUPN741696A0 (en) * 1996-01-05 1996-01-25 Commonwealth Scientific And Industrial Research Organisation Delivery of nucleic acids ii
US5980935A (en) * 1996-05-15 1999-11-09 Kirpotin; Dmitri Cationic lipids and methods of use therefor
GB9623051D0 (en) * 1996-11-06 1997-01-08 Schacht Etienne H Delivery of DNA to target cells in biological systems
US5877220A (en) * 1997-03-06 1999-03-02 Genta, Incorporated Amide-based oligomeric cationic lipids
DE19726186A1 (de) * 1997-06-20 1998-12-24 Boehringer Ingelheim Int Komplexe für den Transport von Nukleinsäure in höhere eukaryotische Zellen
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6740643B2 (en) * 1999-01-21 2004-05-25 Mirus Corporation Compositions and methods for drug delivery using amphiphile binding molecules
US6780327B1 (en) * 1999-02-25 2004-08-24 Pall Corporation Positively charged membrane

Also Published As

Publication number Publication date
AU3366901A (en) 2001-07-16
CN101041079A (zh) 2007-09-26
US20030166601A1 (en) 2003-09-04
CA2395636A1 (en) 2001-07-12
WO2001049324A2 (en) 2001-07-12
WO2001049324A3 (en) 2002-06-06
IL150484A (en) 2010-12-30
JP2003519199A (ja) 2003-06-17
CN1433478A (zh) 2003-07-30
EP1242609A2 (en) 2002-09-25
IL207404A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
IL207404A0 (en) Novel colloid synthetic vectors for gene therapy
EP1223947A4 (en) TARGETED VECTORS
HUP0105208A3 (en) Gene therapy-1
IL146332A0 (en) PrP-LIKE GENE
IL148805A0 (en) Gene transfer vectors
GB9906615D0 (en) Vector
GB0025890D0 (en) Gene therapy
GB0008966D0 (en) Vectors for gene therapy
EP1084236A4 (en) NOVEL ADENOVIRAL VECTORS FOR GENE THERAPY
GB9900009D0 (en) Gene therapy
EP1215284A4 (en) TSG TYPE GENE
GB0406539D0 (en) Gene therapy
EP1225222A4 (en) Tumor suppressor gene
GB0112374D0 (en) Novel protein
GB9909446D0 (en) Vector
GB9816775D0 (en) Herpesviral vectors for gene delivery
EP1182256A4 (en) WITH POLLINOSIS ASSOCIATED GEN 513
GB9920837D0 (en) Gene therapy
GB9902522D0 (en) Truncated vectors
GB9903122D0 (en) Novel gene
AU1555P (en) Maroochy Sundew Fragaria xananassa
AU2790P (en) Diamante Fragaria xananassa
AU2789P (en) Gaviota Fragaria xananassa
GB9928539D0 (en) Novel protein
GB9906713D0 (en) Novel protein